文献速递心脑血管急症重症综合管理与镇静镇痛

预防性抗癫痫药物与脑出血后健康相关生活质量

Prophylactic Seizure Medication and Health-Related Quality of Life After Intracerebral Hemorrhage.
PubMed 文献 · Crit Care Med · 2018-01-01
一句话结论脑出血后预防性使用左乙拉西坦与随访时认知功能健康相关生活质量较低独立相关,T评分低5.1分。

该前瞻性队列研究纳入学术医疗中心142例脑出血存活者,评估预防性左乙拉西坦与健康相关生活质量的关系。主要终点为Neuro-Quality of Life认知功能v2.0 T评分,校正年龄、NIHSS、脑叶出血和评估时间后,接受预防性左乙拉西坦者认知功能T评分低5.1分(p=0.01)。3个月时认知功能T评分较低与左乙拉西坦总剂量较大(p=0.01)和住院期间给药次数较多(p=0.03)相关。左乙拉西坦与改良Rankin量表评分或活动能力健康相关生活质量无独立关联(p>0.1)。

要点

  • 脑出血存活者中,预防性左乙拉西坦与随访时认知功能健康相关生活质量T评分低5.1分独立相关(p=0.01)。
  • 3个月时认知功能T评分较低与左乙拉西坦总剂量较大(p=0.01)及住院期间给药次数较多(p=0.03)相关。
  • 接受预防性左乙拉西坦者脑叶出血比例更高(27/38 vs 19/104,p<0.001),接受脑电图监测比例更高(15/38 vs 21/104,p=0.02)。
  • 接受与未接受预防性左乙拉西坦者临床癫痫发作比例无显著差异(4/38 vs 7/104,p=0.5)。
  • 左乙拉西坦与改良Rankin量表评分或活动能力健康相关生活质量无独立关联(p>0.1)。

适用人群与场景

  • 脑出血存活者,共142例,来自学术医疗中心的前瞻性队列研究。

研究设计与关键结果

  • 研究类型为前瞻性队列研究,纳入142例脑出血存活者,设置于学术医疗中心,无干预。
  • 主要终点为Neuro-Quality of Life认知功能v2.0 T评分(以美国人群为参照,50±10),校正年龄(p=0.3)、美国国立卫生研究院卒中量表评分(p<0.000001)、脑叶出血(p=0.9)和评估时间后,接受预防性左乙拉西坦者认知功能T评分低5.1分(p=0.01);控制预防性左乙拉西坦和脑出血严重程度整体指标脑出血评分的统计模型结果相似。
  • 3个月时认知功能健康相关生活质量T评分较低与左乙拉西坦总剂量较大(p=0.01)和住院期间左乙拉西坦给药次数较多(p=0.03)相关。
  • 接受预防性左乙拉西坦者脑叶出血比例更高(27/38 vs 19/104,p<0.001),接受脑电图监测比例更高(15/38 vs 21/104,p=0.02),临床癫痫发作比例无显著差异(4/38 vs 7/104,p=0.5)。
  • 左乙拉西坦与改良Rankin量表评分或活动能力健康相关生活质量无独立关联(p>0.1)。

证据类型、等级与局限

  • 证据类型:前瞻性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为预防性左乙拉西坦与脑出血后随访时认知功能健康相关生活质量较低独立相关,提示临床决策中需权衡预防性用药的潜在认知影响。
  • 接受预防性左乙拉西坦者脑叶出血比例更高(27/38 vs 19/104,p<0.001),住院期间脑电图监测比例更高(15/38 vs 21/104,p=0.02),但临床癫痫发作比例无显著差异(4/38 vs 7/104,p=0.5)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Prophylactic levetiracetam is currently used in ~40% of patients with intracerebral hemorrhage, and the potential impact of levetircetam on health-related quality of life is unknown. We tested the hypothesis that prophylactic levetiracetam is independently associated with differences in cognitive function health-related quality of life.

DESIGN: Patients with intracerebral hemorrhage were enrolled in a prospective cohort study. We performed mixed models for T-scores of health-related quality of life, referenced to the U.S. population at 50 ± 10, accounting for severity of injury and time to follow-up.

SETTING: Academic medical center.

PATIENTS: One-hundred forty-two survivors of intracerebral hemorrhage.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: T-scores of Neuro-Quality of Life Cognitive Function v2.0 was the primary outcome, whereas Neuro-Quality of Life Mobility v1.0 and modified Rankin Scale (a global functional scale) were secondary measures. We prospectively documented if prophylactic levetiracetam was administered and retrieved administration data from the electronic health record. Patients who received prophylactic levetiracetam had worse cognitive function health-related quality of life (T-score 5.1 points lower; p = 0.01) after adjustment for age (p = 0.3), National Institutes of Health Stroke Scale (p < 0.000001), lobar hematoma (p = 0.9), and time of assessment; statistical models controlling for prophylactic levetiracetam and the Intracerebral Hemorrhage Score, a global measure of intracerebral hemorrhage severity, yielded similar results. Lower T-scores of cognitive function health-related quality of life at 3 months were correlated with more total levetiracetam dosage (p = 0.01) and more administered doses of levetiracetam in the hospital (p = 0.03). Patients who received prophylactic levetiracetam were more likely to have a lobar hematoma (27/38 vs 19/104; p < 0.001), undergo electroencephalography monitoring (15/38 vs 21/104; p = 0.02), but not more likely to have clinical seizures (4/38 vs 7/104; p = 0.5). Levetiracetam was not independently associated with the modified Rankin Scale scores or mobility health-related quality of life (p > 0.1).

CONCLUSIONS: Prophylactic levetiracetam was independently associated with lower cognitive function health-related quality of life at follow-up after intracerebral hemorrhage.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Naidech AM, Beaumont J, Muldoon K, et al. Prophylactic Seizure Medication and Health-Related Quality of Life After Intracerebral Hemorrhage. Crit Care Med. 2018. PMID: 29923930. doi:10.1097/CCM.0000000000003272

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。